• SB4 A METHODOLOGY FOR ASSESSING TREATMENT EFFECT IN THE PRESENCE OF DISEASE SEVERITY AND COMORBIDITY IN RETROSPECTIVE OBSERVATIONAL STUDIES

    May 1, 2011, 00:00

  • PDB46 DEVELOPMENT OF THE DIABETIC PERIPHERAL NEUROPATHIC PAIN IMPACT MEASURE- A PATIENT-REPORTED OUTCOME MEASURE OF THE IMPACT OF DPNP ON FUNCTIONING

    May 1, 2011, 00:00

  • PCV66 ADHERENCE RATES AMONG HEALTH PLAN MEMBERS STARTING GENERIC VERSUS BRAND STATIN THERAPY

    May 1, 2011, 00:00

  • PCV83 GAPS AND UNMET NEEDS IN ANTIPLATELET THERAPIES FOR ACUTE CORONARY SYNDROME (ACS) AND CHRONIC CORONARY HEART DISEASE (CHD)

    May 1, 2011, 00:00

  • PCV22 META REGRESSION ANALYSIS TO INDIRECTLY COMPARE THE SAFETY AND EFFICACY OF DALTEPARIN TO ENOXAPARIN IN PATIENTS WITH UNSTABLE CORONARY ARTERY DISEASE

    May 1, 2011, 00:00

  • PRM15 ADHERENCE IS ADHERENCE IS ADHERENCE- THE CONSISTENCY OF MORISKY ADHERENCE SCORES ACROSS THE COSTLIEST CHRONIC CONDITIONS

    May 1, 2011, 00:00

  • PSS9 COST-EFFECTIVENESS OF COLLAGENASE VERSUS HYDROGEL DRESSINGS FOR CHRONIC-WOUND DEBRIDEMENT IN A LONG-TERM CARE SETTING

    May 1, 2011, 00:00

  • PCV6 ANALYSIS OF MYOCARDIAL INFARCTION RELATED CLINICAL OUTCOMES, HEALTH CARE UTILIZATION AND COSTS OF PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

    May 1, 2011, 00:00

  • PDB59 THE COMPLEXITY OF DRUG THERAPY AND SOCIO-ECONOMIC VARIANTS IN PATIENTS WITH DIABETES

    May 1, 2011, 00:00

  • PMH52 PATIENT AND PHYSICIAN PREFERENCES AND SATISFACTION WITH ORAL AND LONG-ACTING INJECTABLE LONG-TERM ANTIPSYCHOTIC TREATMENT FOR PSHYCHOTIC DISORDERS

    May 1, 2011, 00:00

  • PCN120 WHO CHOSE PRIMARY ANDROGEN DEPRIVATION THERAPY OVER RADICAL PROSTATECTOMY- A RETROSPECTIVE STUDY AMONG VETERANS WITH LOCALIZED PROSTATE CANCER

    May 1, 2011, 00:00

  • PMS47 EMPLOYABILITY-ADJUSTED-LIFE-YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH GOLIMUMAB PLUS METHOTREXATE OR METHOTREXATE ALONE

    May 1, 2011, 00:00

  • PSY1 SEVERE RENAL, HEPATIC AND GASTROINTESTINAL EVENTS ASSOCIATED WITH DEFERASIROX IN PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA

    May 1, 2011, 00:00

  • PHP13 THE IMPACT OF A QUALITY IMPROVEMENT INITIATIVE ON INAPPROPRIATE MEDICATION USE IN THE OUTPATIENT ELDERLY

    May 1, 2011, 00:00

  • PIH27 DIFFERENCES IN PATIENT SATISFACTION WITH PRIMARY CARE AND SPECIALTY CARE

    May 1, 2011, 00:00

  • PCN107 PAYER-RATED VALUE OF PAIN IMPROVEMENT IN CASTRATION-RESISTANT PROSTATE CANCER- TRADEOFFS BETWEEN SURVIVAL, PAIN AND ANALGESIC USE

    May 1, 2011, 00:00

  • PDB56 IMPACT OF PHARMACIST MANAGEMENT ON PATIENTS WITH DIABETES ENROLLED IN A RURAL FREE CLINIC

    May 1, 2011, 00:00

  • PMS53 USE OF TNF-INHIBITORS IN THE UNITED STATES- UTILIZATION PATTERNS AND DOSE-ESCALATION FROM A REPRESENTATIVE UNITED STATES RA POPULATION

    May 1, 2011, 00:00

  • PDB15 SHORT-TERM ASSOCIATION OF ANTIDEPRESSANT DRUG USE, LIFE-STYLE RISK FACTORS AND NEW-ONSET DIABETES

    May 1, 2011, 00:00

  • PMH74 UTILIZATION, PRICE AND SPENDING TRENDS FOR SEROTONIN–NOREPINEPHRINE REUPTAKE INHIBITORS IN THE UNITED STATES MEDICAID PROGRAM- 1991-2009

    May 1, 2011, 00:00

  • PCV34 PROPHYLAXIS USE AND 90-DAY COSTS FOR VENOUS THROMBOEMBOLISM, MAJOR AND MINOR BLEEDING EVENT ANALYSIS IN HOSPITALIZED MEDICALLY ILL PATIENTS

    May 1, 2011, 00:00

  • PIN10 ECOMOMIC EVALUATION OF DAPTOMYCIN COMPARE WITH STANDARD THERAPY IN THE TREATMENT OF STAPHYLOCOCCUS AUREUS BACTEREMIA WITH OR WITHOUT ENDOCARDITIS IN COLOMBIA

    May 1, 2011, 00:00

  • PRS15 ECONOMIC EVALUATION OF FLUTICASONE FUROATE COMPARED WITH MOMETASONA FUROATE FOR THE PRIMARY TREATMENT OF ALLERGIC RHINITIS PATIENTS

    May 1, 2011, 00:00

  • PRM9 PHARMACOECONOMICS IN REPUBLIC OF KAZAKHSTAN

    May 1, 2011, 00:00

  • PMD11 IDENTIFYING POTENTIAL DRIVERS OF COST SAVINGS WITH INSULIN ADMINISTRATION DEVICES IN TYPE-2 DIABETES IN THE UNITED STATES

    May 1, 2011, 00:00

  • PRS32 HOSPITAL COST VERSUS MEDICARE PAYMENT FOR RESPIRATORY INSUFFICIENCY, ARREST AND FAILURE

    May 1, 2011, 00:00

  • PCN130 RECORD-LINKAGE FOR PHARMACOEPIDEMIOLOGIC STUDIES IN CANCER PATIENTS

    May 1, 2011, 00:00

  • PSY33 EXPLORING THE FACTOR STRUCTURE OF THE PROMIS FATIGUE ITEM BANK IN PATIENTS WITH FIBROMYALGIA

    May 1, 2011, 00:00

  • PSY20 ECONOMIC EVALUATION OF SEQUENTIAL ANALGESIC TREATMENT IN THE MANAGEMENT OF MODERATE ANKLE SPRAIN IN MEXICAN ADULTS

    May 1, 2011, 00:00

  • IN2 ASSOCIATION BETWEEN DRUG TOLERABILITY AND ECONOMIC IMPACT FOR PROPHYLAXIS OF INVASIVE FUNGAL INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT

    May 1, 2011, 00:00

  • PCN4 BODY MASS INDEX AND STAGE OF DIAGNOSIS OF OVARIAN CANCER- A SYSTEMATIC REVIEW AND META-ANALYSIS

    May 1, 2011, 00:00

  • PCV100 HEALTH CARE UTILIZATION AND COSTS FOR A MEDICATION THERAPY MANAGEMENT (MTM) PROGRAM

    May 1, 2011, 00:00

  • PSY29 A COMPARISON OF DAILY AVERAGE SUPPLY (DASUP) OF OXYCODONE AND OXYMORPHONE LONG-ACTING ORAL TABLETS

    May 1, 2011, 00:00

  • PDB62 RELATIONSHIP BETWEEN SOCIAL AND ECONOMIC FACTORS AND ANTIDIABETIC MEDICATION PRESCRIBING PATTERNS

    May 1, 2011, 00:00

  • PCV88 PATTERNS OF STATIN PRESCRIPTION AMONG PRIVATELY INSURED COMMERCIAL AND MEDICARE PATIENTS

    May 1, 2011, 00:00

  • PSS12 A DISCRETE EVENT SIMULATION TO OPTIMISE THE ALLOCATION OF CONSTRAINED HOSPITAL RESOURCES FOR GLAUCOMA

    May 1, 2011, 00:00

  • PCN125 MELODY BRASIL- TREATMENT PATTERNS AND ASSOCIATED COSTS OF METASTATIC MELANOMA PATIENTS IN THE BRAZILIAN PUBLIC HEALTH SYSTEM (SUS)

    May 1, 2011, 00:00

  • PGI23 WORK PRODUCTIVITY AMONG GENOTYPE 1 HEPATITIS C VIRUS (HCV) TREATMENT-NAÏVE PATIENTS RECEIVING TELAPREVIR-BASED TREATMENT REGIMENS- RESULTS FROM ADVANCE AND ILLUMINATE STUDIES

    May 1, 2011, 00:00

  • PMS3 RISK FACTORS FOR NON-INITIATION OF DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (DMARD) BY PATIENTS WITH NEWLY DIAGNOSED RHEUMATOID ARTHRITIS (RA)

    May 1, 2011, 00:00

  • PCN109 TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION OF METASTATIC PROSTATE CANCER PATIENTS BY PHYSICIAN SPECIALTY

    May 1, 2011, 00:00

  • PMH9 RISK OF DEATH IN DUAL ELIGIBLE NURSING HOME RESIDENTS USING ANTIPSYCHOTIC AGENTS

    May 1, 2011, 00:00

  • PMS39 MOST EFFECTIVE ADHERENCE-ENHANCING INTERVENTIONS FOR OSTEOPOROSIS MEDICATIONS

    May 1, 2011, 00:00

  • PSS30 BURDEN OF INFANTILE HEMANGIOMA- DEVELOPMENT OF A QUESTIONNAIRE

    May 1, 2011, 00:00

  • PRS41 A REAL-WORLD EVALUATION OF BETA AGONIST USE DURING HOSPITALIZATIONS FOR COPD

    May 1, 2011, 00:00

  • PSY51 EFFECTIVENESS OF FDA'S NEW OVER-THE-COUNTER ACETAMINOPHEN LABEL WARNING REQUIREMENTS IN IMPROVING CONSUMER RISK PERCEPTION OF LIVER DAMAGE

    May 1, 2011, 00:00

  • PDB20 BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF SAXAGLIPTIN IN THE TREATMENT OF TYPE-2 DIABETES IN CHILE

    May 1, 2011, 00:00

  • PCV12 IMPACT OF POTENTIAL DRUG-DRUG INTERACTIONS (DDIS) ON HEALTH OUTCOMES AND COST TO MEDICAID- THE MONETARY BENFITS OF QUALITY HEALTH CARE

    May 1, 2011, 00:00

  • PMH56 COMPARISON OF DIFFERENT COMORBIDITY MEASURES FOR PREDICTING PHYSICAL AND MENTAL HEALTH IN DEMENTIA

    May 1, 2011, 00:00

  • PCN19 AN EPIDEMIOLOGICAL MODEL OF BREAST CANCER AND PROGRESSION TO BONE METASTASES IN THE UNITED KINGDOM

    May 1, 2011, 00:00

  • PUK11 UPDATED ECONOMIC ANALYSIS OF FESOTERODINE RELATIVE TO TOLTERODINE AND SOLIFENACIN FOR THE TREATMENT OF OVERACTIVE BLADDER- THE SWEDISH PERSPECTIVE

    May 1, 2011, 00:00

  • PSY65 CHARACTERISTICS OF GOLIMUMAB UTILIZATION IN A LARGE NATIONAL PAYER DATABASE

    May 1, 2011, 00:00

  • PMS44 ASSESSING VITALITY IN PATIENTS UNDERGOING ETANERCEPT THERAPY FOR RHEUMATOID ARTHRITIS

    May 1, 2011, 00:00

  • CN2 ESTIMATED EFFECTS OF THE NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM ON CERVICAL CANCER MORTALITY

    May 1, 2011, 00:00

  • PCV18 MEDICATION ADHERENCE AND HOSPITALIZATION AMONG CHRONIC HEART FAILURE MEDICARE BENEFICIARIES WITH AND WITHOUT DEPRESSION

    May 1, 2011, 00:00

  • PCN16 MAJOR CHANGES IN CHEMOTHERAPY REGIMENS ADMINISTERED TO BREAST CANCER PATIENTS DURING 2000-2008

    May 1, 2011, 00:00

  • PMS71 COMPARISON OF PROPENSITY SCORE MATCHING AND INSTRUMENTAL VARIABLE METHODS WHEN ESTIMATING HEALTH CARE COSTS OF RHEUMATOID ARTHRITIS PATIENTS

    May 1, 2011, 00:00

  • PHP111 OVER INFLATION OF THE GENETIC CONTRIBUTION TO SCHIZOPHRENIA- IMPLICATIONS FOR NOVEL THERAPEUTICS

    May 1, 2011, 00:00

  • PCV48 COST-EFFECTIVENESS ANALYSIS OF ANTIARRHYTHMIC THERAPIES FOR THE TREATMENT OF SUPRAVENTRICULAR TACHYCARDIA AND SURGICALLY INDUCED TACHYCARDIAS AND HYPERTENSION

    May 1, 2011, 00:00

  • PSU18 IMPACT OF HEALTH INSURANCE ON RECEIVING BREAST CONSERVING SURGERY WITH RADIATION IN FLORIDA

    May 1, 2011, 00:00

  • PRM13 COMPARISON OF DISCRETE EVENTS SIMULATION SOFTWARE FOR USE IN HEALTH ECONOMICS OUTCOMES RESEARCH

    May 1, 2011, 00:00

  • PCN1 CHEMOTHERAPY INDUCED NAUSEA AND VOMITING EVENT RATE AMONG PATIENTS WITH CANCER TREATED WITH HIGHLY OR MODERATELY EMETOGENIC CHEMOTHERAPY AND INITIATED ON PALONOSETRON VERSUS OTHER 5-HT3-RECEPTOR ANTAGONIST ANTI-EMETIC PROPHYLAXIS IN A ...

    May 1, 2011, 00:00

  • PDB74 BETA-VERIFICATION OF A DIABETES MODELING FRAMEWORK AGAINST PUBLISHED COHORT TRIALS

    May 1, 2011, 00:00

  • PCN115 A CROSS-COUNTRY COMPARISON OF SECOND-LINE MULTIPLE MYELOMA TREATMENTS

    May 1, 2011, 00:00

  • PSY19 THE COST-EFFECTIVENESS OF BORTEZOMIB PLUS MELPHALAN AND PREDNISONE VERSUS LENALIDOMIDE PLUS MELPHALAN AND PREDNISONE WITH CONTINUOUS LENALIDOMIDE MAINTENANCE TREATMENT FOR THE INITIAL TREATMENT OF MULTIPLE MYELOMA IN THE UNITED STATES ...

    May 1, 2011, 00:00

  • PCN135 ECONOMIC CONSEQUENCES OF PREVENTABLE BLADDER TUMOR RECURRENCES IN NON-MUSCLE INVASIVE BLADDER CANCER

    May 1, 2011, 00:00

  • PMH76 PHARMACIST AND PHARMACY STAFF KNOWLEDGE AND ATTITUDES TOWARDS SUICIDE AND SUICIDE PREVENTION AFTER A NATIONAL VA TRAINING PROGRAM

    May 1, 2011, 00:00

  • CE1 COST-EFFECTIVENESS SENSITIVITY ANALYSIS METHODS- A COMPARISON OF ONE-WAY SENSITIVITY, ANALYSIS OF COVARIANCE, AND EXPECTED VALUE OF PARTIAL PERFECT INFORMATION

    May 1, 2011, 00:00

  • PCN129 USE OF ELECTRONIC MEDICAL RECORDS (EMR) FOR ONCOLOGY OUTCOMES RESEARCH- ASSESSING THE COMPARABILITY OF EMR INFORMATION TO PATIENT REGISTRY AND HEALTH CLAIMS DATA

    May 1, 2011, 00:00

  • PIN22 COST-EFFECTIVENESS OF A CATCH-UP DOSE OF HEPATITIS B VACCINE IN COLOMBIAN ADOLESCENTS

    May 1, 2011, 00:00

  • PMH23 COMPARISON OF HEALTH CARE COSTS AND UTILIZATIONS BETWEEN PATIENTS WHO WERE TREATED WITH AND WITHOUT MEDICATION FOR OPIOID DEPENDENCY

    May 1, 2011, 00:00

  • PSY7 A NOVEL MECHANISM OF CAPTURING POST-MARKETING SAFETY INFORMATION ON RECOMBINANT FACTOR VIIA (RFVIIA) IN THE RARE DISORDER ACQUIRED HEMOPHILIA- THE ACQUIRED HEMOPHILIA SURVEILLANCE (AHS) PROJECT

    May 1, 2011, 00:00

  • PRS1 SEVERE ASTHMA EXACERBATIONS ASSOCIATED WITH LONG-ACTING BETA AGONISTS AMONG CHILDREN AND ADOLESCENTS WITH ASTHMA

    May 1, 2011, 00:00

  • PSY8 DIRECT AND INDIRECT COSTS OF PRIVATELY-INSURED PATIENTS TREATED WITH OXYMORPHONE EXTENDED-RELEASE OR OXYCODONE CONTROLLED-RELEASE TABLETS

    May 1, 2011, 00:00

  • PCV23 COMPARING THE EFFECTIVENESS OF ROSUVASTATIN AND ATORVASTATIN IN PREVENTING CARDIOVASCULAR OUTCOMES- ESTIMATES USING THE ARCHIMEDES MODEL

    May 1, 2011, 00:00

  • PIH30 POSTPARTUM DEPRESSION IN VULNERABLE PEOPLE IN SOUTH KOREA

    May 1, 2011, 00:00

  • PSY36 DEVELOPMENT OF THE LUPUS IMPACT TRACKER- A TOOL FOR PATIENTS AND PHYSICIANS TO ASSESS AND MONITOR THE IMPACT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

    May 1, 2011, 00:00

  • PUK18 THE IMPACT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) ON PATIENTS' HEALTH RELATED QUALITY OF LIFE (HRQOL)- DEVELOPMENT OF A CONCEPTUAL FRAMEWORK

    May 1, 2011, 00:00

  • PMD39 MINI-HTA TRENDS FOR MEDICAL DEVICES IN THE NORDICS

    May 1, 2011, 00:00

  • PMH73 RETROSPECTIVE ANALYSIS OF THE IMPACT OF PERSISTENCE ON HEALTH CARE CHARGES AMONG OPIOID-DEPENDENT PATIENTS TREATED WITH BUPRENORPHINE/NALOXONE USING AN INSURANCE DATABASE IN THE UNITED STATES

    May 1, 2011, 00:00

  • PMS40 HOW DOES OSTEOARTHRITIS SEVERITY INFLUENCE PATIENT PREFERENCES AND WILLINGNESS TO PAY FOR OSTEOARTHRITIS TREATMENTS?

    May 1, 2011, 00:00

  • MD2 PRESCRIPTION DRUG COST AND USE IN THE MEDICARE PART D POPULATION - USES OF A NEW LIMITED DATA SET

    May 1, 2011, 00:00

  • PHP68 THE 15 YEARS EXPERIENCE OF NEW DRUGS ADOPTION AND REIMBURSEMENT IN TAIWAN'S NATIONAL HEALTH INSURANCE

    May 1, 2011, 00:00

  • PHP86 IRRATIONAL USE OF ANTIBIOTICS AND ROLE OF PHARMACISTS- AN INSIGHT FROM A QUALITATIVE STUDY IN NEW DELHI, INDIA

    May 1, 2011, 00:00

  • PND1 PRESCRIBING PATTERNS OF DRUGS HAVING ANTICHOLINERGIC ACTIVITY IN PATIENTS WITH ALZHEIMER'S DISEASE

    May 1, 2011, 00:00

  • PIN35 CLINICAL EFFECTIVENESS AND COST UTILITY OF ENTECAVIR VERSUS LAMIVUDINE AND ADEFOVIR IN CHRONIC HEPATITIS B VIRUS (HBV) PATIENTS IN MEXICO

    May 1, 2011, 00:00

  • PCV106 RE-HOSPITALIZATION RATES OF ACUTE CORONARY SYNDROME PATIENTS IN REAL WORLD CLINICAL PRACTICE- OBSERVATIONS FROM A NATIONAL ADMINISTRATIVE CLAIMS DATA

    May 1, 2011, 00:00

  • PHP30 CAN PRICING SCHEMES IMPROVE MARKET ACCESS FOR INNOVATIVE HIGH PRICED DRUGS?

    May 1, 2011, 00:00

  • IN3 COSTS ASSOCIATED WITH HCV AND RELATED COMPLICATIONS IN THE UNITED STATES FROM A MANAGED CARE PAYER'S PERSPECTIVE

    May 1, 2011, 00:00

  • PCN128 LINKING MEDICARE, MEDICAID AND CANCER REGISTRY DATA TO STUDY BURDEN OF CANCERS IN WEST VIRGINIA (FUNDING- AHRQ - R24 HS018622-01)

    May 1, 2011, 00:00

  • PSY54 APPLICATION OF THE NON-LINEAR BLINDER-OAXACA DECOMPOSITION TO STUDY RACIAL/ETHNIC DISPARITIES IN ANTI-OBESITY MEDICATION USE

    May 1, 2011, 00:00

  • IN1 MEASUREMENT OF SYMPTOMS AND IMPACT OF INFLUENZA- DEVELOPMENT OF THE SYMPTOM INTENSITY AND IMPACT OF INFLUENZA QUESTIONNAIRE (FLU-IIQ)

    May 1, 2011, 00:00

  • PND46 THE IMPACT OF EPILEPSY ON ADULT AND PAEDIATRIC PATIENT'S LIVES- A CONCEPTUAL MODEL

    May 1, 2011, 00:00

  • PCN82 IMPACT OF OPTIMAL CML RESPONSE ON PATIENT SATISFACTION AND QUALITY OF LIFE- A PATIENT SURVEY FROM THE ASSOCIATION OF CANCER ONLINE RESOURCES (ACOR) DATABASE

    May 1, 2011, 00:00

  • PRS13 ECONOMIC CONSEQUENSES OF USING TULATHROMYCIN, FLORFENICOL, AND TILMICOSIN FOR TREATMENT OF CATTLE AT HIGH RISK OF DEVELOPING BOVINE RESPIRATORY DISEASE IN UNITED STATES FEEDLOTS

    May 1, 2011, 00:00

  • PMS20 HEALTH CARE RESOURCES UTILIZATION IN THE MANAGEMENT OF JUVENILE IDIOPATHIC ARTHRITIS- ANALYSES WITH THE RAMQ DATABASE

    May 1, 2011, 00:00

  • PMH60 BIPOLAR DISORDER RESULTS IN SIGNIFICANT BURDEN ON CAREGIVERS- ANALYSIS OF DATA FROM A LARGE MULTINATIONAL LONGITUDINAL STUDY (WAVE-BD)

    May 1, 2011, 00:00

  • PMH48 AMBER TODD

    May 1, 2011, 00:00

  • PHP22 ASSOCIATION OF SELF-REPORTED HEALTH STATUS WITH COST-RELATED MEDICATION NONADHERENCE AND OUT-OF-POCKET PHARMACY SPENDING AMONG SENIOR MEDICARE BENEFICIARIES

    May 1, 2011, 00:00

  • PHP71 IMPACT OF THE MEDICARE PART D COVERAGE GAP ON PRESCRIPTION DRUG UTILIZATION AND MEDICATION ADHERENCE

    May 1, 2011, 00:00

  • PRS35 PHARMACY QUALITY INDICATORS USING MISSISSIPPI MEDICAID- TESTING PQA-ENDORSED STARTER SET MEASURES AND 2010 TEST MEASURES

    May 1, 2011, 00:00

  • PMH83 ESTIMATING SAMPLE SIZE FOR PSYCHOMETRIC STUDIES USING CONFIRMATORY FACTOR ANALYSIS

    May 1, 2011, 00:00

  • PIN25 COST-EFFECTIVENESS ANALYSIS OF THE INTRODUCTION OF THE VARICELLA VACCINE IN COLOMBIA

    May 1, 2011, 00:00

  • PMS37 INDIRECT COMPARISON OF ADALIMUMAB VERSUS ETANERCEPT FOR THE TREATMENT OF PSORIATIC ARTHRITIS

    May 1, 2011, 00:00

  • MC3 IMPACT OF MULTIPLE MEDICATION COMPLIANCE ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE II DIABETES AND COMORBID HYPERTENSION CONTROLLING FOR ENDOGENEITY BIAS

    May 1, 2011, 00:00

  • PSU22 A PATIENT-BASED QUESTIONANIRE TO ASSESS OUTCOMES OF FOOT SURGERY- VALIDATION IN THE CONTEXT OF SURGERY FOR HALLUX VALGUS

    May 1, 2011, 00:00

  • PMH53 ASSESSING THE IMPACT OF MAJOR DEPRESSIVE DISORDER (MDD) ON FAMILY FUNCTIONING- DEVELOPMENT OF THE DEPRESSION AND FAMILY FUNCTIONING SCALE

    May 1, 2011, 00:00

  • PCV69 IMPACT OF COMMUNITY PHARMACIST-LED COUNSELING ON IMPROVING MEDICATION ADHRERENCE

    May 1, 2011, 00:00

  • PND19 HUMANISTIC AND ECONOMIC BURDEN IN TUBEROUS SCLEROSIS COMPLEX WITH NEUROLOGICAL MANIFESTATIONS- SYSTEMATIC REVIEW

    May 1, 2011, 00:00

  • PDB42 ADHERENCE TO ROUTINE OR STRUCTURED GLUCOSE MONITORING- A QUALITATIVE EVALUATION FROM THE STEP STUDY

    May 1, 2011, 00:00

  • PSY37 THE PAIN MANAGEMENT IS ALWAYS A PUBLIC HEALTH CHALLENGE

    May 1, 2011, 00:00

  • PRM23 MEASURING THE IMPACT OF PREVIOUS TREATMENT CYCLES ON HEALTH UTILITY IN PATIENTS RECEIVING BOTULINUM TOXIN TYPE A (BONTA) IN A PROSPECTIVE OBSERVATIONAL COHORT STUDY- MOBILITY STUDY

    May 1, 2011, 00:00

  • PDB44 A NOVEL APPROACH FOR NON-ADHERENCE MEASUREMENT BASED ON PRESCRIPTION DATA- THE EXAMPLE OF ORAL DIABETICS IN THE THERAPY OF TYPE-2 DIABETES MELLITUS PATIENTS

    May 1, 2011, 00:00

  • PDB19 ECONOMIC ASSESSMENT OF CONVERSION TO INSULIN PEN DEVICES IN A LONG TERM CARE FACILITY CHAIN

    May 1, 2011, 00:00

  • PCN123 A SYSTEMATIC REVIEW OF TREATMENT GUIDELINES FOR METASTATIC COLORECTAL CANCER

    May 1, 2011, 00:00

  • PCN137 COMPREHENSIVE REVIEW OF MANAGEMENT EFFICIENCY STRATEGIES AMONG ONCOLOGY PRACTICES- EXISTING EVIDENCE AND OPPORTUNITIES FOR FUTURE RESEARCH

    May 1, 2011, 00:00

  • PMS7 THE IMPACT OF RHEUMATOID ARTHRITIS ON CARDIOVASCULAR MORBIDITY IN A HIGH RISK MEDICAID POPULATION

    May 1, 2011, 00:00

  • CE3 COST-EFFECTIVENESS ANALYSIS AND BUDGET IMPACT ASSESSMENT- A GRAPHICAL WAY TO COMBINE THE TWO FOR THE AID OF DECISION-MAKERS

    May 1, 2011, 00:00

  • PCV60 MEDICATION ADHERENCE, PERSISTENCE, AND HEALTH CARE COSTS FOR PATIENTS INITIATING STATIN THERAPY IN A MANAGED CARE POPULATION

    May 1, 2011, 00:00

  • PCN38 FIRST-YEAR COSTS FOR THE 19 MOST COMMON CANCER DIAGNOSES IN ONTARIO

    May 1, 2011, 00:00

  • PCN91 ARTHRALGIA AND PATIENT-REPORTED OUTCOMES IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER TAKING AROMATASE INHIBITORS- LONGITUDINAL ANALYSES

    May 1, 2011, 00:00

  • PHP35 DECISION MAKING IN BRAZIL BASED ON HEALTH TECHNOLOGY ASSESSMENT- THE GOOD, THE BAD, AND THE FUTURE

    May 1, 2011, 00:00

  • PMH15 IMPACT OF ADHERENCE TO FIRST THERAPY ON THE RISK OF ANTIDEPRESSANT SWITCHING

    May 1, 2011, 00:00

  • PMH35 COMPARISONS OF MENTAL HEALTH-RELATED MEDICAL CARE UTILIZATION AND COSTS FOLLOWING THE INITIATION OF ORAL VERSUS LONG-ACTING INJECTABLE RISPERIDONE IN PATIENTS WITH SCHIZOPHRENIA

    May 1, 2011, 00:00

  • PMH3 RISK OF HIP FRACTURES IN ELDERLY MEDICARE BENEFICIARIES USING ATYPICAL OR TYPICAL ANTIPSYCHOTICS- A PROPENSITY SCORE ANALYSIS

    May 1, 2011, 00:00

  • PSU9 ECONOMIC EVALUATION OF THE CURRENT TREND TOWARDS MORE UNCEMENTED FIXATION IN PRIMARY HIP ARTHROPLASTIES AND THE POTENTIAL IMPACT OF CHANGES OF THE DEVELOPMENT IN ENGLAND AND WALES

    May 1, 2011, 00:00

  • PMS50 PATTERNS OF TREATMENT UTILIZATION FOR OSTEOPOROSIS IN ELDERLY WOMEN RESIDING IN THE COMMUNITY AND IN LONG-TERM CARE FACILITIES

    May 1, 2011, 00:00

  • PRS42 CONCOMITANT ASTHMA MEDICATION USE IN PATIENTS USING OMALIZUMAB- RESULTS FROM THREE LARGE INSURANCE CLAIMS DATABASES

    May 1, 2011, 00:00

  • DU1 COMPARATIVE SAFETY OF STIMULANT AND ATOMOXETINE ASSOCIATED WITH THE RISK OF SUBSTANCE USE DISORDER AMONG ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER

    May 1, 2011, 00:00

  • PSY55 NATIONAL TRENDS IN ANTI-OBESITY MEDICATION USE FROM 2002 TO 2007

    May 1, 2011, 00:00

  • PRS28 EVALUATING THE IMPACT OF PHYSICIAN PROVIDED ASTHMA EDUCATION ON ABSENTEEISM IN CHILDREN- USING DATA FROM THE NATIONAL HEALTH INTERVIEW SURVEY (NHIS)

    May 1, 2011, 00:00

  • PCV93 HEALTH EXPENDITURE COMPARISON OF METOPROLOL SUCCINATE VS METOPROLOL TARTARATE

    May 1, 2011, 00:00

  • PDB13 USE OF ANTIDEPRESSANTS AND THE RISK OF DIABETES MELLITUS- A RETROSPECTIVE COHORT STUDY

    May 1, 2011, 00:00

  • EV2 PAYERS AND PROS- BEYOND QOL

    May 1, 2011, 00:00

  • PHP1 USE OF STRUCTURAL EQUATION MODELING TO EXPLAIN CONSUMER BEHAVIOR TOWARDS GENERIC DRUG DISCOUNT PROGRAMS

    May 1, 2011, 00:00

  • PMH84 PERFORMANCE OF TWO INSTRUMENTAL VARIABLES TO EXAMINE THE RISK OF DEATH IN DUAL ELIGIBLE ELDERLY NURSING HOME RESIDENTS USING ANTIPSYCHOTIC AGENTS

    May 1, 2011, 00:00

  • PCV112 EXTENSION OF META-ANALYSIS IN COMPARING OF FIMASARTAN WITH LOSARTAN IN BLOOD PRESSURE LOWERING EFFECT

    May 1, 2011, 00:00

  • PIH17 COST-EFFECTIVENESS OF ABLE A FUNCTIONAL PROGRAM TO DECREASE MORTALITY IN COMMUNITY-DWELLING OLDER ADULTS

    May 1, 2011, 00:00

  • PMH24 COMPARISON OF HEALTH CARE COSTS AND UTILIZATIONS BETWEEN PATIENTS WHO WERE TREATED WITH PHARMACOLOGICAL AND NON-PHARMACOLOGICAL SUBSTANCE MEDICATIONS FOR ALCOHOL DEPENDENCY

    May 1, 2011, 00:00

  • PRS39 EFFECT OF BIOMASS SMOKE ON CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN RURAL LOCALITIES OF COLOMBIA

    May 1, 2011, 00:00

  • PDB18 FACTORS ASSOCIATED WITH ROUTINE PROPER MONITORING OF DIABETES CARE AMONG THE NON-INSTITUTIONALIZED POPULATION IN THE UNITED STATES- A RETROSPECTIVE ANALYSIS OF THE 2007 MEDICAL EXPENDITURE PANEL SURVEY (MEPS)

    May 1, 2011, 00:00

  • PCN75 ECONOMIC EVALUATION OF DASATINIB IN CHRONIC MYELOGENOUS LEUKAEMIA PATIENTS RESISTANT TO IMATINIB IN PERU, COMPARED TO NILOTINIB AND HIGH DOSES OF IMATINIB

    May 1, 2011, 00:00

  • PMD38 META ANALYSIS OF THE IMPACT OF HEALTH INFORMATION TECHNOLOGY ON MEDICATION SAFETY IN HOSPITALS- AN INTERRUPTED TIME SERIES STUDY

    May 1, 2011, 00:00

  • PSY22 ANALYSING THE BENEFITS AND COST SAVING OF ORAL VERSUS IV FLUDARABINE FOR MANAGEMENT OF B-CELL CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)

    May 1, 2011, 00:00

  • PCV99 MEDICAL RESOURCE UTILIZATION AND COSTS FOLLOWING HOSPITALIZATION OF PATIENTS WITH CHRONIC HEART FAILURE IN THE UNITED STATES

    May 1, 2011, 00:00

  • PHP50 MIXED EVIDENCE FOR THE ”HEALTHY ADHERER EFFECT” IN A SAMPLE OF 22,070 ADULTS WITH CHRONIC DISEASE IN THE UNITED STATES

    May 1, 2011, 00:00

  • PMH69 HEALTH CARE RESOURCE UTILIZATION AMONG PATIENTS WITH BIPOLAR DISORDER- RETROSPECTIVE DATA FROM A LARGE MULTINATIONAL LONGITUDINAL STUDY (WAVE-BD)

    May 1, 2011, 00:00

  • PIN52 MAPPING STATE AND FEDERAL IMMUNIZATION RECORDS POLICIES

    May 1, 2011, 00:00

  • PRS19 COST-UTILITY OF VARENICLINE VERSUS INTERVENTIONS AVAILABLE FOR QUITTING SMOKING IN PANAMA USING THE BENESCO MODEL

    May 1, 2011, 00:00

  • PCV70 VARIATIONS IN THE IMPACT OF ILLNESS PERCEPTIONS AND MEDICATION BELIEFS ON MEDICATION COMPLIANCE OF ELDERLY VERSUS GERIATRIC HYPERTENSIVE COHORTS- A COMPARATIVE ANALYSIS

    May 1, 2011, 00:00

  • PCN49 THE RELATIONSHIP OF AGE AND SEX WITH COST OF TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA IN UKRAINE

    May 1, 2011, 00:00

  • PCV46 LONG-TERM COSTS AND HEALTH OUTCOMES OF TREATING ACUTE CORONARY SYNDROME PATIENTS WITH TICAGRELOR BASED ON THE EU LABEL - COST-EFFECTIVENESS ANALYSIS BASED ON THE PLATO STUDY

    May 1, 2011, 00:00

  • PSU23 ASSESSING THE OUTCOME OF SHOULDER SURGERY- DEVELOPMENT, VALIDATION AND RESPONSIVENESS OF THE PATIENT-REPORTED OXFORD SHOULDER SCORE (OSS)

    May 1, 2011, 00:00

  • PND55 USE OF TIME-TO-EVENT ANALYSES TO DEFINE EPISODES OF CARE IN SICKLE CELL DISEASE

    May 1, 2011, 00:00

  • PMH51 BASELINE RESULTS FROM BEAT THE BLUES

    May 1, 2011, 00:00

  • PMS22 COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN MEXICO

    May 1, 2011, 00:00

  • PND26 MEASURING THE IMPACT OF NATALIZUMAB THERAPY ON HEALTH CARE UTILIZATION IN A COMMERCIALY MANAGED MULTIPLE SCLEROSIS POPULATION

    May 1, 2011, 00:00

  • PSU2 USING ELECTRONIC MEDICAL RECORDS TO IDENTIFY POTENTIAL PREDICTORS FOR BARIATRIC SURGERY SUCCESS

    May 1, 2011, 00:00

  • IN4 CARDIOVASCULAR DISEASE SCREENING IN HIV-INFECTED PATIENTS – A COST-EFFECTIVENESS ANALYSIS

    May 1, 2011, 00:00

  • PMS70 A COMPARISON OF NON-RESPONDER IMPUTATION AND LAST-OBSERVATION-CARRIED-FORWARD ANALYSIS METHODS IN RHEUMATOID ARTHRITIS CLINICAL TRIALS

    May 1, 2011, 00:00

  • PHP74 CLINICAL TRIAL LEARNING CURVES AFFECT OUTCOMES MEASUREMENT, PATIENT SAFETY AND TRIAL SUCCESS- CONTRIBUTING FACTORS AND A POTENTIAL SOLUTION IN CLINICAL TRIAL SIMULATION

    May 1, 2011, 00:00

  • PDB33 EVALUATING THE COST-EFFECTIVENESS OF SWITCHING FROM INSULIN GLARGINE TO INSULIN DETEMIR IN PATIENTS WITH TYPE-2 DIABETES IN A CHINESE SETTING- A MODELING STUDY BASED ON THE PREDICTIVE STUDY

    May 1, 2011, 00:00

  • PCN74 UTILISATION OF DRUGS INVOLVED IN TREATMENT OF STAGE I AND STAGE II BREAST CANCER IN SLOVAK REPUBLIC

    May 1, 2011, 00:00

  • PCN34 LONG-TERM DIRECT MEDICAL COSTS IN PATIENTS DIAGNOSED WITH FOLLICULAR LYMPHOMA WHO RECEIVE FRONTLINE CHEMOTHERAPY WITH VERSUS WITHOUT RITUXIMAB - A SEER MEDICARE ANALYSIS

    May 1, 2011, 00:00

  • PHP48 STATUS OF PHARMACIST AT COMMUNITY LEVEL- AN EXPLORATORY STUDY IN QUETTA, PAKISTAN

    May 1, 2011, 00:00

  • EE4 BOOTSTRAPPING USED TO PROVIDE ROBUST MEAN AND VARIANCE ESTIMATES FOR COMPARING PATIENTS TREATED WITH LIRAGLUTIDE TO A LARGE COMPARISON COHORT

    May 1, 2011, 00:00

  • PUK23 METHODOLOGICAL CONSIDERATIONS FOR COST-EFFECTIVENESS ANALYSIS OF ONABOTULINUMTOXINA IN PATIENTS WITH NEUROGENIC DETRUSOR OVERACTIVITY

    May 1, 2011, 00:00

  • PIH7 POTENTIALLY INAPPROPRIATE MEDICATION USE AMONG OLDER ADULTS IN THE UNITED STATES IN 2007

    May 1, 2011, 00:00

  • PND15 THE INCREMENTAL COST OF ALZHEIMER'S DISEASE IN THE CALIFORNIA MEDICAID PROGRAM (MEDI-CAL)

    May 1, 2011, 00:00

  • DM4 EVALUATION OF CLINICAL LABORATORY-PHARMACY LINKAGE DECISION SUPPORT IN THE USE OF POTASSIUM SUPPLEMENTS

    May 1, 2011, 00:00

  • PSY16 PROJECTING THE LIFETIME ECONOMIC COSTS OF OBESITY- A BMI TRAJECTORY-BASED MODEL

    May 1, 2011, 00:00

  • PSS7 MEDICAL CARE COSTS ASSOCIATED WITH VISION LOSS IN TAIWAN

    May 1, 2011, 00:00

  • PND64 APPLICATION OF PREDICTIVE MODELING TO CLASSIFY FREQUENT SNORING IDENTIFIED FROM ROUTINE MEDICAL EXAMINATIONS USING THE NHANES DATABASE

    May 1, 2011, 00:00

  • PCV4 TREATMENT PATTERNS, CLINICAL AND ECONOMIC BURDEN OF VENOUS THROMBOEMBOLISM IN ABDOMINAL SURGERY PATIENTS

    May 1, 2011, 00:00

  • PHP59 THE AVAILABILITY AND SIGNIFICANCE OF COST-EFFECTIVENESS DATA FOR INFORMING DECISIONS TO ADD NEW DRUGS TO THE NATIONAL LIST OF HEALTH SERVICES IN ISRAEL

    May 1, 2011, 00:00

  • PMS60 PATIENT OUTCOMES ASSOCIATED WITH BIOLOGIC INFUSION SITE OF CARE FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

    May 1, 2011, 00:00

  • PSY45 CHARACTERISTICS OF CAREGIVERS AND THEIR EXPERIENCE ASSOCIATED WITH CONGENITAL HEMOPHILIA OF INHIBITOR PATIENTS

    May 1, 2011, 00:00

  • PCV15 PREDICTORS OF THE COMBINED DIAGNOSIS HYPERLIPIDEMIA AND HYPERTENSION - A NHANES 2007-2008 STUDY

    May 1, 2011, 00:00

  • PCN29 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) USING RITUXIMAB (R) WITH FLUDARABINE (F) AND CYCLOPHOSPHAMIDE (C)- ASSESSING THE FINANCIAL IMPACT OF THE ROUTE OF ADMINISTRATION AT PRINCESS MARGARET HOSPITAL (PMH)

    May 1, 2011, 00:00

  • PCN63 EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION TESTING AND FIRST LINE TREATMENT WITH GEFITINIB IS A DOMINANT STRATEGY IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

    May 1, 2011, 00:00

  • PMH45 MEASURES OF MEDICATION ADHERENCE IN ORAL VERSUS LONG-ACTING RISPERIDONE IN TEXAS MEDICAID PATIENTS WITH SCHIZOPHRENIA

    May 1, 2011, 00:00

  • PRM30 RESULTS FROM A NEW VISUAL ANALOGUE SCALE PROTOCOL FOR EQ-5D VALUATIONS

    May 1, 2011, 00:00

  • PIN48 TRENDS IN FUNDING OF SPECIALIST VACCINES

    May 1, 2011, 00:00

  • PSY40 EPIDEMIOLOGY OF HEREDITARY COAGULOPATHIES IN UKRAINE- PATIENT-REPORTED DATA

    May 1, 2011, 00:00

  • PMD12 GENDER DIFFERENCES IN TOTAL KNEE ARTHROPLASTY (TKA) POSTOPERATIVE PAIN MANAGEMENT IN THE UNITED STATES

    May 1, 2011, 00:00

  • PMD6 READMISSION RATES AND COSTS ASSOCIATED WITH FIBRIN SEALANT USE AMONG PATIENTS UNDERGOING ORTHOPEDIC SURGERY

    May 1, 2011, 00:00

  • PMS54 ESTIMATING THE ECONOMIC BENEFITS OF POSITIVE SHIFTS IN FIBROMYALGIA SEVERITY

    May 1, 2011, 00:00

  • PIH19 COSTS AND EFFECTS OF A MULTIFACETED INTERVENTION TO IMPROVE THE QUALITY OF CARE OF CHILDREN IN DISTRICT HOSPITALS IN KENYA

    May 1, 2011, 00:00

  • ISPOR 16TH Annual International Meeting Research Abstracts Author Index

    May 1, 2011, 00:00

  • PND8 INCIDENCE RATES OF SUBARACHNOID HEMORRHAGE IN PATIENTS WITH UNRUPTURED ANEURYSM IN SOUTH KOREA FROM 2006-2009

    May 1, 2011, 00:00

  • PMS17 EVALUATING THE ASSOCIATION BETWEEN SERUM URIC ACID LEVEL AND HEALTH CARE COSTS IN PATIENTS WITH GOUT

    May 1, 2011, 00:00

  • PMS62 ASSOCIATION OF SATISFACTION WITH SUBCUTANEOUS ANTI-TNF THERAPY AND CLINICAL OUTCOMES, HEALTH STATUS, AND LOST WORK PRODUCTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS

    May 1, 2011, 00:00

  • CE2 A NOVEL WAY OF ESTIMATING COST-EFFECTIVENESS RATIOS FROM CLINICAL TRIALS WITH MISSING DATA- A SIMULATION STUDY

    May 1, 2011, 00:00

  • PHP81 CAREGIVER WELL-BEING AND HEALTH CARE ACCESS AND QUALITY AMONG CHILDREN WITH CHRONIC PHYSICAL AND MENTAL CONDITIONS

    May 1, 2011, 00:00

  • PCN81 DIVERSITY IN BELIEFS ABOUT THE CAUSES OF CANCER- A QUALITATIVE APPROACH TO EVALUATE CANCER PATIENTS' UNDERSTANDING TOWARDS CANCER AND ITS CAUSES

    May 1, 2011, 00:00

  • SB2 ZEROS AND NON-REPORTED HEALTH CARE AND WORKPLACE PRODUCTIVITY DATA- AN APPLICATION OF TWO-STAGE ESTIMATION TECHNIQUES MEASURING INPATIENT COSTS AND ABSENTEEISM ASSOCIATED WITH LOW BACK AND NECK PAIN

    May 1, 2011, 00:00

  • PIH4 COMPARATIVE EFFECTIVENESS OF BANKED DONOR MILK FOR PREMATURE INFANTS- EFFICIENCY OF A MILK BANK MODEL INTEGRATED IN A BLOOD BANK SETTING

    May 1, 2011, 00:00

  • PMH67 CO-PRESCRIBING CHOLINESTERASE INHIBITORS WITH ANTICHOLINERGIC URINARY INCONTINENCE MEDICATIONS

    May 1, 2011, 00:00

  • PCN21 PATTERNS OF ANGIOGENESIS INHIBITOR TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) IN IRELAND

    May 1, 2011, 00:00

  • PRM21 CONVERTING PAPER VERSIONS OF PATIENT REPORTED OUTCOME INSTRUMENTS TO ELECTRONIC VERSIONS- IDENTIFYING THE REQUIRED STEPS

    May 1, 2011, 00:00

  • PHP11 REVIEW OF ADJUSTMENT OF ESSENTIAL MEDICINE LIST AT PROVINCIAL LEVEL IN CHINA

    May 1, 2011, 00:00

  • PHP9 IMPACT OF FREE PRESCRIPTIONS IN WALES ON PRESCRIBING - A THIN DATABASE STUDY

    May 1, 2011, 00:00

  • PMH1 IS STIMULANT OR ATOMOXETINE UTILIZATION ASSOCIATED WITH NEUROLOGICAL ADVERSE EVENTS IN CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)? A RETROSPECTIVE ANALYSIS OF PROPENSITY SCORE MATCHED DATA

    May 1, 2011, 00:00

  • PMS43 QUALITY OF LIFE AND FIBROMYALGIA - A SYSTEMATIC LITERATURE REVIEW

    May 1, 2011, 00:00

  • PCN42 COSTS OF HOSPITAL EVENTS IN PATIENTS WITH METASTATIC COLORECTAL CANCER

    May 1, 2011, 00:00

  • PCV10 THE EFFECT OF INTERACTIONS BETWEEN CLOPIDOGREL AND PROTON PUMP INHIBITORS ON ADVERSE CARDIOVASCULAR OUTCOMES IN COMMERCIALLY INSURED PATIENTS WITH ACUTE CORONARY SYNDROME

    May 1, 2011, 00:00

  • PSS10 A COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT FOR THE TREATMENT OF MODERATE AND SEVERE PSORIASIS IN MEXICO

    May 1, 2011, 00:00

  • PSY14 ECONOMIC IMPACT OF POTENTIAL DRUG-DRUG INTERACTIONS AMONG PATIENTS TAKING OPIOID ANALGESICS

    May 1, 2011, 00:00

  • PCN100 RACIAL DISPARITIES IN AFRICAN AMERICAN VERSUS WHITE WOMEN WITH NEWLY DIAGNOSED BREAST CANCER IN A SOUTHEAST UNITED STATES HEALTH PLAN

    May 1, 2011, 00:00

  • PDB52 A LITERATURE REVIEW OF DIABETES RISK ASSESSMENT TOOLS

    May 1, 2011, 00:00

  • PCV110 DEVELOPMENT AND VALIDATION OF A SHORT PRO MEASURE OF HEALTH STATUS FOR INDIVIDUALS WITH ACUTE MYOCARDIAL INFARCTION- THE MYOCARDIAL INFARCTION DIMENSIONAL ASSESSMENT SCALE (MIDAS)

    May 1, 2011, 00:00

  • PND34 MAPPING THE INSOMNIA SEVERITY INDEX (ISI) TO THE EQ-5D UTILITIES

    May 1, 2011, 00:00

  • PSU13 MORBID OBESITY AND HEALTH RELATED QUALITY OF LIFE

    May 1, 2011, 00:00

  • PCV21 EFFECTS OF AZILSARTAN MEDOXOMIL VERSUS VALSARTAN AND OLMESARTAN MEDOXOMIL ON THE ACHIEVEMENT OF SYSTOLIC BLOOD PRESSURE GOALS AMONG HYPERTENSIVE PATIENTS WITH DIABETES

    May 1, 2011, 00:00

  • PHP47 ADVERSE DRUG EVENTS AND ELECTRONIC MEDICAL RECORDS- RESULTS FROM THE 2007-2008 NATIONAL AMBULATORY MEDICAL CARE SURVEY

    May 1, 2011, 00:00

  • PGI14 PERCEIVED VALUE ASSESSMENT OF ENTECAVIR VERSUS TENOFOVIR IN CHRONIC HEPATITIS B

    May 1, 2011, 00:00

  • PCN48 IMPACT ON HOSPITAL OUTPATIENT VISIT COSTS BY INITIATING PALONOSETRON VERSUS OTHER 5-HYDROXYTRYPTAMINE3 RECEPTOR ANTAGONISTS FOR PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) AMONG PATIENTS WITH CANCER

    May 1, 2011, 00:00

  • PND17 IMPACT OF WALKING AND MOBILITY PROBLEMS ON REQUIREMENT FOR HEALTHCARE AMONG MULTIPLE SCLEROSIS PATIENTS

    May 1, 2011, 00:00

  • PMS25 COST-EFFECTIVENESS OF ABATACEPT OR INFLIXIMAB IN RHEUMATOID ARTHRITIS IN COLOMBIA

    May 1, 2011, 00:00

  • PIH39 THE EFFECT OF ELECTRONIC-MEDICAL-RECORD SYSTEM SOPHISTICATION ON PREVENTIVE HEALTH CARE FOR WOMEN

    May 1, 2011, 00:00

  • PMS72 SUITABILITY OF THE EFFICIENCY FRONTIER APPROACH FOR THE EVALUATION OF BIOLOGICAL AGENTS IN THE TREATMENT OF EARLY RHEUMATOID ARTHRITIS

    May 1, 2011, 00:00

  • PDB60 EFFECT OF MEDICARE PART D COVERAGE GAP ON MEDICATION CONSUMPTION BEHAVIORS- CASE OF ORAL ANTI-DIABETIC MEDICATIONS

    May 1, 2011, 00:00

  • PRM3 THE BURDEN OF CAREGIVING- ASSESSING THE STATUS OF CURRENT CLINICAL RESEARCH

    May 1, 2011, 00:00

  • PCV81 SUSTAINING CLINICAL OUTCOMES OVER 24 MONTHS- IS MEDICATION THERAPY MANAGEMENT (MTM) THE ANSWER?

    May 1, 2011, 00:00

  • PUK13 COST-EFFECTIVENESS ANALYSIS OF THE EARLY CONVERSION OF TACROLIMUS TO MTOR INHIBITORS IN PATIENTS WITH RENAL TRANSPLANTATION

    May 1, 2011, 00:00

  • DS4 BURDEN OF PROOF…PROOF OF PRINCIPLE- REPLICATION QUANTIFICATION, REPLICATION AND VALIDATION… STANDARDS OF EVIDENCE IN OUTCOMES RESEARCH SURROGATE ENDPOINTS FOR ALL-CAUSE MORTALITY

    May 1, 2011, 00:00

  • PRS5 CIGARETTE SMOKING AMONG JORDANIAN ADULTS- PREDICTORS AND CORRELATES

    May 1, 2011, 00:00

  • PGI12 DOSE VARIATIONS WITH ADALIMUMAB AND INFLIXIMAB IN THE TREATMENT OF CROHN'S DISEASE- A CANADIAN ASSESSMENT

    May 1, 2011, 00:00

  • PCN124 CLINICAL AND DEMOGRAPHIC CHARACTERISTICS OF CHRONIC MYELOGENOUS LEUKEMIA PATIENTS TREATED AT PUBLIC ONCOLOGY CLINICS IN SÃO PAULO, BRAZIL

    May 1, 2011, 00:00

  • PCV92 CHANGES IN THE PREVALENCE, TREATMENT AND CONTROL OF HYPERTENSION IN GERMANY? A CLINICAL-EPIDEMIOLOGICAL EXAMINATION OF 50,000 PRIMARY CARE PATIENTS WITH THE DETECT STUDY

    May 1, 2011, 00:00

  • PND41 PARNETING STRESS IN CARING FOR CHILDREN DIAGNOSED WITH NEURO-DEVELOPMENTAL DISORDER

    May 1, 2011, 00:00

  • PMD22 COST-EFFECTIVENESS ANALYSIS OF THREE WOUND DRESSINGS FOR THE TREATMENT OF PRESSURE ULCERS FROM THE PUBLIC HOSPITAL PERSPECTIVE

    May 1, 2011, 00:00

  • PUK19 KIT73- PRELIMINARY REPORTS OF IMMUNOSUPRESSANT THERAPY PATTERNS IN A COHORT OF POST KIDNEY TRANSPLANT PATIENTS IN BRAZIL

    May 1, 2011, 00:00

  • PDB24 DIRECT HEALTHCARE AND INDIRECT WORKLOSS COSTS ASSOCIATED WITH THE ADDITION OF ROSIGLITAZONE (RSG) VERSUS SITAGLIPTIN (STG) THERAPY TO METFORMIN (MET)

    May 1, 2011, 00:00

  • PIN47 CRITICAL SUCCESS FACTORS FOR THE UPTAKE OF NOVEL VACCINES ONTO NATIONAL IMMUNUSATION PROGRAMMES

    May 1, 2011, 00:00

  • PRS37 THE PRICE NEGOTIATION ON PHARMACEUTICALS AFTER THE INTRODUCTION OF POSITIVE LIST SYSTEM IN SOUTH KOREA

    May 1, 2011, 00:00

  • PMS51 RACIAL DISPARITIES IN UTILIZATION OF BIOLOGIC AND DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN A CALIFORNIA MEDICAID POPULATION WITH RHEUMATOID ARTHRITIS

    May 1, 2011, 00:00

  • PMS27 A COST-EFFECTIVENESS ANALYSIS FROM AN INSTITUTIONAL PERSPECTIVE TO COMPARE ZOLEDRONIC ACID WITH STANDARD OF CARE IN THE PREVENTION OF HIP FRACTURES IN PATIENTS WITH OSTEOPOROSIS

    May 1, 2011, 00:00

  • PMH71 HEALTH CARE RESOURCE UTILIZATION (HRU) AND DIRECT MEDICAL EXPENDITURES (DME) FOR ADULT WOMEN WITH ANXIETY DISORDERS (AD) IN THE UNITED STATES IN 2006 USING MEDICAL EXPENDITURES PANEL SURVEY (MEPS)

    May 1, 2011, 00:00

  • PSS14 COST-UTILITY ANALYSIS OF RANIBIZUMAB (LUCENTIS®) IN WET-AMD BASED ON REAL-LIFE DATA COLLECTED IN THE HELIOS STUDY AFTER RANIBIZUMAB REIMBURSEMENT IN BELGIUM

    May 1, 2011, 00:00

  • PSY31 HEMOPHILIA A- PATIENT IMPACT AND ECONOMIC BURDEN OF THE DISEASE

    May 1, 2011, 00:00

  • PIH8 THE ECONOMIC IMPACT ATTRIBUTABLE TO THE INAPPROPRIATE PRESCRIPTION OF BENZODIAZEPINES IN THE ELDERLY LIVING IN THE COMMUNITY

    May 1, 2011, 00:00

  • PSY72 VARIATION BY AGE IN HEALTH-RELATED QUALITY OF LIFE OF PATIENTS INITIATING TREATMENT FOR MYELODYSPLASTIC SYNDROMES

    May 1, 2011, 00:00

  • PRM4 WHAT IS IMPORTANT DURING THE PHARMACOECONOMIC EVALUATION OF CAM (COMPLEMENTARY AND ALTERNATIVE MEDICINE)?—A SURVEY RESEARCH

    May 1, 2011, 00:00

  • PSU10 COST-EFFECTIVENESS OF PRIMARY PCI WITHOUT ONSITE SURGICAL BACKUP

    May 1, 2011, 00:00

  • PRM40 ISSUES CONCERNING THE TRANSLATION OF THE WORD ‘HASSLED' IN THE MORISKY MEDICATION ADHERENCE SCALE (MMAS-8)

    May 1, 2011, 00:00

  • OR4 ASSOCIATIONS BETWEEN JOBLESSNESS AND ALL-CAUSE HEALTH SERVICES UTILIZATION IN DIABETIC WORKING AGE ADULTS IN THE UNITED STATES

    May 1, 2011, 00:00

  • PCV52 COST-EFFECTIVNESS STUDY OF CITICOLINE IN PATIENTS WITH ACUTE ISCHEMIC STROKE IN RUSSIA

    May 1, 2011, 00:00

  • PIN21 COST EFFECTIVENESS ANALYSIS OF VACCINATION PROGRAMS WITH 10-VALENT (PCV10) AND 13-VALENT (PCV13) PNEUMOCOCCAL VACCINES IN COLOMBIA

    May 1, 2011, 00:00

  • PCV17 PREDICTORS OF TIME TO DISCONTINUE BETA-BLOCKER FOLLOWING ACUTE MYOCARDIAL INFARCTION- AN ANALYSIS OF THE MEDICARE 5% NATIONAL SAMPLE DATA 2006-2007

    May 1, 2011, 00:00

  • PRS31 DEVELOPMENT OF A QUESTIONNAIRE ASSESSING THE BURDEN OF PRURITUS

    May 1, 2011, 00:00

  • PMS45 WILLINGNESS TO PAY FOR OSTEOPOROSIS TREATMENT TO PREVENT FRACTURE IN KOREAN POPULATION

    May 1, 2011, 00:00

  • PCN71 USING MEASURES OF SOCIETAL VALUE AND ECONOMIC MODELING TO ESTIMATE PRICES FOR CANCER DRUGS IN SOUTH AFRICA

    May 1, 2011, 00:00

  • PMS11 APPLYING THE STRATIFIED PROPENSITY SCORE MATCHING METHOD WHEN ESTIMATING HEALTH CARE COSTS OF RHEUMATOID ARTHRITIS PATIENTS

    May 1, 2011, 00:00

  • PMH82 VALIDATION AND PSYCHOMETRIC EVALUATION OF A BRIEF COMBINED ASSESSMENT OF DEPRESSION AND ANXIETY

    May 1, 2011, 00:00

  • PRM41 IS IT TIME TO ELIMINATE THE ICER? USING NET BENEFITS TO REPORT THE RESULTS OF DETERMINISTIC COST-EFFECTIVENESS ANALYSES

    May 1, 2011, 00:00

  • PIH13 THE COST-EFFECTIVENESS OF THE LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (LNG-IUS, MIRENA®) FOR THE TREATMENT OF HEAVY MENSTRUAL BLEEDING IN THE UNITED STATES

    May 1, 2011, 00:00

  • PRS3 RELATIVE EFFECTIVENESS STUDY OF OMALIZUMAB- THE USE OF BEFORE-AFTER COHORT METHODOLOGY FOR COVERAGE WITH EVIDENCE DEVELOPMENT

    May 1, 2011, 00:00

  • PMH17 PREVALENCE OF ANTICHOLINERGIC DRUG PRESCRIBING IN ELDERLY OUTPATIENTS WITH DEMENTIA

    May 1, 2011, 00:00

  • PSS19 PSYCHOMETRIC EVALUATION OF THE NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE 25 AND VISUAL FUNCTION QUESTIONNAIRE UTILITY INDEX IN PATIENTS WITH NON-INFECTIOUS INTERMEDIATE AND POSTERIOR UVEITIS

    May 1, 2011, 00:00

  • PHP83 HTA DECISION DRIVERS FOR ACCEPTANCE OF HIGH ICER SUBMISSIONS AND REJECTION OF LOW ICER SUBMISSIONS

    May 1, 2011, 00:00

  • PSY76 TREATMENT OF CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS) KNOWLEDGE STUDY (TOCKS)- NOVEL DATA COLLECTION, VIEWING AND DYNAMIC REPORTING MECHANISM

    May 1, 2011, 00:00

  • PND47 THE HEMOPHILIA UTILIZATION GROUP STUDY (HUGS-VB)- HEALTH-RELATED QUALITY OF LIFE IN HEMOPHILIA B

    May 1, 2011, 00:00

  • PCV61 THE IMPACT OF THE MEDICARE DOUGHNUT HOLE ON MEDICATION USE BEHAVIORS AND HEALTH CARE RESOURCE UTILIZATION AMONG BENEFICIARIES TAKING STATIN MEDICATION

    May 1, 2011, 00:00

  • PIH21 COST-UTILITY ANALYSIS OF DIENOGEST VERSUS GNRH ANALOGUE IN THE TREATMENT OF ENDOMETRIOSIS-ASSOCIATED PELVIC PAIN IN SLOVAKIA

    May 1, 2011, 00:00

  • PMS16 COST OF RHEUMATOID ARTHRITIS PATIENTS RECEIVING TNF-ANTAGONIST THERAPY FROM THE KOREA NATIONAL HEALTH INSURANCE CLAIMS DATABASE

    May 1, 2011, 00:00

  • PND20 HEALTHCARE UTILIZATION AND COSTS AMONG AD PATIENTS WITH AND WITHOUT DYSPHAGIA

    May 1, 2011, 00:00

  • PCN30 DOES A LACK OF HTA REVIEW LEAD TO HIGHER PRICES FOR HIV TREATMENTS? A COMPARISON WITH ONCOLOGY TREATMENTS

    May 1, 2011, 00:00

  • PGI26 PATIENT CHARACTERISTICS ASSOCIATED WITH USE OF ENTERAL VERSUS PARENTERAL ACID SUPPRESSIVE AGENTS IN INTENSIVE CARE UNIT PATIENTS

    May 1, 2011, 00:00

  • PDB63 GEOGRAPHIC VARIATION IN DRUG SPENDING AND ADHERENCE PATTERNS FOR MEDICARE BENEFICIARIES WITH DIABETES

    May 1, 2011, 00:00

  • PHP114 OPTIMIZING THE ORGANIZATION; MIGRATING HEALTH SERVICES RESEARCH OPERATIONS INTO THE COLLABORATIVE SCIENCE CENTER OF EXCELLENCE

    May 1, 2011, 00:00

  • PRM28 CREATION OF A NEW PSORIASIS QUALITY OF LIFE MEASURE FROM FIVE PREEXISTENT INSTRUMENTS USING RASCH ANALYSIS- THE CALIPSO QUESTIONNAIRE

    May 1, 2011, 00:00

  • PIN37 HOW MANY IMMUNIZATION DOSES WERE MISSED IN PEDIATRICES YOUNGER THAN 2 YEARS?

    May 1, 2011, 00:00

  • PCN56 COST-EFFECTIVENESS OF TEMSIROLIMUS FOR METASTIC RENAL-CELL CARCINOMA AND POOR PROGNOSIS PATIENTS IN MEXICO

    May 1, 2011, 00:00

  • PND30 QUALITY OF LIFE AMONG PATIENTS SUFFERING FROM MIGRAINE- HEALTH UTILITY BY FREQUENCY OF HEADACHE DAYS

    May 1, 2011, 00:00

  • PSU4 SURGEON'S VOLUME-OUTCOMES RELATIONSHIP FOR LOBECTOMIES AND WEDGE RESECTIONS FOR CANCER USING VIDEO-ASSISTED THORACOSCOPIC TECHNIQUES

    May 1, 2011, 00:00

  • PMS30 COST-UTILITY ANALYSIS OF DENOSUMAB VERSUS STANDARD CARE IN THE TREATMENT OF POST-MENOPAUSAL OSTEOPOROSIS IN PORTUGAL

    May 1, 2011, 00:00

  • PCN27 COMPARATIVE BUDGET IMPACT OF FORMULARY INCLUSION OF ZOLEDRONIC ACID AND DENOSUMAB FOR PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES

    May 1, 2011, 00:00

  • PIH16 COST-EFFECTIVENESS OF DESVENLAFAXINE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS IN BREAST CANCER PATIENTS IN MEXICO

    May 1, 2011, 00:00

  • PIN13 IMPACT OF NEWLY DIAGNOSED HEPATITIS C INFECTIONS ON HEALTH CARE COSTS

    May 1, 2011, 00:00

  • PUK1 INCIDENCE AND 30-DAY MORTALITY OF COMMUNITY ACQUIRED PNEUMONIA (CAP) IN THE MEDICARE FEE-FOR-SERVICE (FFS) POPULATION

    May 1, 2011, 00:00

  • PCN12 RESOURCE UTILIZATION AND PERCEPTIONS OF MAJOR MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA (CML)- RESULTS OF A DELPHI PANEL STUDY

    May 1, 2011, 00:00

  • PSY13 THE COST OF OBESITY AND ITS MAJOR COMORBIDITIES- ANALYSIS FROM A COMMERCIAL CLAIMS DATABASE

    May 1, 2011, 00:00

  • PCV87 FACTORS ASSOCIATED WITH SELECTIONS OF STATINS AMONG ELDERLY PATIENTS

    May 1, 2011, 00:00

  • PMH2 RISK OF HOSPITALIZATION FOR PNEUMONIA ASSOCIATED WITH THE USE OF ATYPICAL VERSUS TYPICAL ANTIPSYCHOTICS IN A NATIONAL SAMPLE OF MEDICARE BENEFICIARIES

    May 1, 2011, 00:00

  • PMS36 EXAMINING THE RELATIONSHIP BETWEEN MONTHLY OUT-OF-POCKET HEALTHCARE COSTS AND WORK PRODUCTIVITY AMONG INDIVIDUALS WITH RHEUMATOID ARTHRITIS

    May 1, 2011, 00:00

  • PCN116 TRANSFERABILITY OF NICE RECOMMENDATIONS FOR PHARMACEUTICAL THERAPIES IN ONCOLOGY TO CENTRAL-EASTERN EUROPEAN COUNTRIES

    May 1, 2011, 00:00

  • PCN88 ATTITUDES OF YOUNG WOMEN ON HUMAN PAPILLOMA VIRUS VACCINATION

    May 1, 2011, 00:00

  • PRS45 MODELING THE IMPACT OF MULTIPLE QUIT ATTEMPTS IN SMOKERS USING DISCRETE EVENT SIMULATION (DES)

    May 1, 2011, 00:00

  • PRM19 NON-RESPONSE BIAS IN A SURVEY ASSESSING PATIENTS' MEDICATION AND HEALTH BELIEFS

    May 1, 2011, 00:00

  • PMH5 PSYCHIATRIC ADVERSE EFFECTS RELATED TO PRESCRIPTION OF METHYLPHENIDATE IN TAIWAN

    May 1, 2011, 00:00

  • PCV14 DYSPEPSIA AND DISEASE BURDEN AMONG PATIENTS WITH ATRIAL FIBRILLATION (AF)

    May 1, 2011, 00:00

  • PDB69 EXENATIDE (BID) AND LIRAGLUTIDE (QD) TREATMENT PATTERNS AMONG TYPE-2 DIABETES PATIENTS IN GERMANY

    May 1, 2011, 00:00

  • MC1 COMPARISON OF REFILL GAP ANALYSIS METHODOLOGIES IN A POPULATION OF PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING ADALIMUMAB OR ETANERCEPT

    May 1, 2011, 00:00

  • PHP27 CANADIAN PUBLIC DRUG PROGRAM SPENDING ON SENIORS, 2002 TO 2008

    May 1, 2011, 00:00

  • PND49 MEASUREMENT CHARACTERISTICS OF THE SF-36 IN PARKINSON'S DISEASE

    May 1, 2011, 00:00

  • OR1 THE ASSOCIATION BETWEEN SELF-PERCEIVED COGNITIVE DIFFICULTIES AND LEVEL OF DEPRESSION AMONG EMPLOYEES WITH CURRENT DEPRESSION

    May 1, 2011, 00:00

  • PMS64 PATIENT EXPERIENCE WITH SUBCUTANEOUS ANTI-TNF THERAPY AMONG RHEUMATOID ARTHRITIS PATIENTS

    May 1, 2011, 00:00

  • PSY50 PRESCRIPTION MONITORING PROGRAMS' UTILIZATION

    May 1, 2011, 00:00

  • PRM42 VISUALLY EVALUATING THE MEASUREMENT COMPARABILITY BETWEEN PAPER-BASED AND ALTERNATE VERSIONS OF ADMINISTRATION OF THE LUNG FUNCTION QUESTIONNAIRE

    May 1, 2011, 00:00

  • PHP76 THE OUTLOOK OF LARGE SIMPLE TRIALS FOR COMPARATIVE EFFECTIVENESS RESEARCH- AN APPLICATION OF THE PRECIS FRAMEWORK

    May 1, 2011, 00:00

  • PDB31 BENEFITS AND COSTS OF CONDUCTING SPONSORED CLINICAL TRIALS IN A PUBLICLY FUNDED NEW ZEALAND HOSPITAL- PRE-TRIAL, TRIAL AND FOLLOW-UP

    May 1, 2011, 00:00

  • PND60 TESTING A COMPUTERIZED METHOD OF ASSESSING MOVEMENT ACCURACY

    May 1, 2011, 00:00

  • PGI10 EXAMINATION OF RESOURCE UTILIZATION PATTERNS ACROSS SUBGROUPS OF GASTROESOPHAGEAL REFLUX DISEASE PATIENTS

    May 1, 2011, 00:00

  • CN3 THE VALUE OF RESEARCH FOR ERCC1 TESTING IN STAGE I NON-SMALL CELL LUNG CANCER

    May 1, 2011, 00:00

  • PHP102 WHICH CRITERIA ARE USED IN HEALTH CARE DECISIONMAKING AND PRIORITY SETTING? A LITERATURE REVIEW FOR AN INTERNATIONAL SURVEY OF DECISIONMAKERS

    May 1, 2011, 00:00

  • PHP112 DEFINITIONAL CRITERIA FOR CHRONIC FATIGUE SYNDROME- A CRITICAL REVIEW

    May 1, 2011, 00:00

  • PND62 MEDICATION POSSESSION RATIO (MPR)- A COMPARISON OF TRADITIONAL MPR AND MODIFIED MPR FOR MULTIPLE SCLEROSIS (MS) PATIENTS PRESCRIBED DISEASE MODIFYING DRUGS (DMDS)

    May 1, 2011, 00:00

  • PSY39 EPIDEMIOLOGY OF HEREDITARY COAGULOPATHIES IN KAZAKHSTAN- PATIENT-REPORTED DATA

    May 1, 2011, 00:00

  • PCN80 PATIENT PREFERENCES FOR TOXICITIES ASSOCIATED WITH CHEMOTHERAPIES FOR ADVANCED BREAST CANCER

    May 1, 2011, 00:00

  • PGI11 THE ECONOMIC AND QUALITY OF LIFE BURDEN OF ILLNESS IN CHRONIC CONSTIPATION (CC) AND IRRITABLE BOWEL SYNDROME (IBS)- A SYSTEMATIC REVIEW

    May 1, 2011, 00:00

  • PMH7 LIKELIHOOD OF POTENTIAL DRUG-DRUG INTERACTIONS AMONG PERSONS INITIATING THERAPY WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS- EFFECT OF INITIAL SSRI AND OTHER FACTORS

    May 1, 2011, 00:00

  • PMD41 SELECTING A SECONDARY DATA SOURCE FOR A LOW-VOLUME PROCEDURE IN A SPECIALTY POPULATION- A STUDY USING INPATIENT PEDIATRIC COLONOSCOPY

    May 1, 2011, 00:00

  • PIN43 UTILIZATION AND SPENDING OF ANTIFUNGAL AGENTS IN THE UNITED STATES OUTPATIENT MEDICAID POPULATION- 1991-2009

    May 1, 2011, 00:00

  • PSY23 ECONOMIC EVALUATION OF ERYTHROPOIESIS STIMULATING AGENTS IN CRITICALLY ILL TRAUMA PATIENTS

    May 1, 2011, 00:00

  • PUK3 DRUG-INDUCED ACUTE RENAL FAILURE USING THE FDA ADVERSE EVENT REPORTING SYSTEM DATABASE

    May 1, 2011, 00:00

  • PIN34 INTRANASAL LIVE ATTENUATED (LAIV) VERSUS INJECTABLE INACTIVATED (TIV) INFLUENZA VACCINE FOR CHILDREN AND ADOLESCENTS- A CANADIAN COST EFFECTIVENESS ANALYSIS

    May 1, 2011, 00:00

  • PSS29 DEVELOPMENT OF THE MODIFIED OCULAR COMFORT INDEX (MOCI)

    May 1, 2011, 00:00

  • PCN72 GENE EXPRESSION PROFILING FOR GUIDING ADJUVANT CHEMOTHERAPY DECISIONS IN WOMEN WITH EARLY BREAST CANCER- A COST-EFFECTIVENESS ANALYSIS OF 1000 STRATEGIES FOR THE PROVISION OF ADJUVANT! ONLINE, ONCOTYPE DX AND CHEMOTHERAPY

    May 1, 2011, 00:00

  • PSY47 WILLINGNESS TO PAY (WTP) FOR WEIGHT LOSS COACHING- RESULTS FROM THE POWER TRIAL

    May 1, 2011, 00:00

  • PHP79 ROLE OF HTA SYSTEMS IN REIMBURSEMENT AND MARKET ACCESS- COMPARISON OF TURKEY AND POLAND

    May 1, 2011, 00:00

  • PDB16 DIABETES MELLITUS TYPE 2 AND T2DM PLUS HYPERTENSION IN BRAZIL- THE EPIDEMIOLOGIC PROFILE OF THE POPULATION REGISTERED IN THE GOVERNMENT PROGRAM HIPERDIA

    May 1, 2011, 00:00

  • PDB28 COST SAVINGS IN TYPE-2 DIABETES (T2D) WITH INSULIN GLARGINE COMPARED WITH INSULIN DETEMIR IN THE UNITED KINGDOM

    May 1, 2011, 00:00

  • PMH34 MEASURING THE IMPACT OF PERSISTENCE WITH PSYCHOTROPIC DRUG THERAPY ON TREATMENT COSTS FOR PATIENTS WITH SCHIZOPHRENIA

    May 1, 2011, 00:00

  • PSY3 OPIOIDS IN NON-MALIGNANT PAIN- ARE THEY EQUIVALENT IN SAFETY PROFILE? A NETWORK META-ANALYSIS

    May 1, 2011, 00:00

  • PIH41 SUCCESSFUL SEXUAL INTERCOURSE- TIME-TO-EVENT MODELING IN A SILDENAFIL TRIAL

    May 1, 2011, 00:00

  • QA1 COST-EFFECTIVENESS OF DUTASTERIDE AS A CHEMOPREVENTION IN PROSTATE CANCER- REDUCE WITHIN-TRIAL ANALYSIS

    May 1, 2011, 00:00

  • PRM11 WHY ALGORITHM DOESN'T MATTER IN SYNDROMIC SURVEILLANCE- A COMPARISON OF SYNDROME CLASSIFICATION METHODS

    May 1, 2011, 00:00

  • PMH59 DIFFERENCES IN BASELINE PROBLEM SEVERITY BETWEEN PRESCRIPTION AND STREET OPIOID ABUSERS AMELIORATED AFTER PARTICIPATION IN DISEASE MANAGEMENT PROGRAM- RESULTS AT ONE YEAR

    May 1, 2011, 00:00

  • PGI9 COMPARISON OF DIRECT MEDICAL COSTS AND SERVICES BY POINT OF SERVICE AND PRESCRIPTION COST FOR PERSONS WITH HEPATITIS-C WITH AND WITHOUT TREATMENT

    May 1, 2011, 00:00

  • SB3 INNOVATIVE DESIGN FOR A COMPARATIVE EFFECTIVENESS STUDY OF SCHIZOPHRENIA TREATMENTS- ANALYSIS OF RECORD REVIEW DATA INCORPORATING RANDOMIZATION AND PROPENSITY SCORE MATCHING

    May 1, 2011, 00:00

  • PUK15 THE COST-EFFECTIVENESS OF LANTHANUM CARBONATE IN THE TREATMENT OF HYPERPHOSPHATEMIA IN DIALYSIS PATIENTS FROM A CANADIAN PERSPECTIVE

    May 1, 2011, 00:00

  • PCN105 ESTIMATING NICE'S COST EFFECTIVE THRESHOLD FOR END-OF-LIFE CANCER TREATMENTS

    May 1, 2011, 00:00

  • PND32 HEALTH RESOURCE UTILIZATION AND COSTS FOR MIGRANEURS IN SCOTLAND

    May 1, 2011, 00:00

  • PCN102 SYNCHRONIZATION OF ADMINISTRATIONS OF CHEMOTHERAPY AND ERYTHROPOIESIS-STIMULATING AGENTS AND FREQUENCY OF ASSOCIATED HEALTH CARE VISITS

    May 1, 2011, 00:00

  • PDB14 USING HEALTH OUTCOMES MODELING TO ASSESS THE BENEFIT-RISK PROFILE OF EXENATIDE ONCE-WEEKLY VERSUS INSULIN GLARGINE FOR PATIENTS WITH TYPE-2 DIABETES

    May 1, 2011, 00:00

  • PSY77 COMPARISON OF OBESITY-ASSOCIATED COMORBIDITIES BETWEEN EMR AND CLAIMS DATABASES

    May 1, 2011, 00:00

  • PRM20 TRENDS IN UTILITY ELICITATION METHODS- DIRECT VERSUS INDIRECT METHODS

    May 1, 2011, 00:00

  • PIH38 EPIDEMIOLOGY OF ADOLESCENT AND YOUNG ADULT HOSPITAL UTILIZATION FOR ALCOHOL AND DRUG USE, SUICIDE, AND POISONING IN THE UNITED STATES

    May 1, 2011, 00:00

  • PCV45 COST-EFFECTIVENESS OF CYP2C9 AND VKORC1 GENOTYPE-GUIDED WARFARIN ANTICOAGULATION CARE- THE IMPLEMENTATION OF DISCRETE EVENT SIMULATION MODEL ON THE NATURAL HISTORY OF VENOUS THROMBOEMBOLISM

    May 1, 2011, 00:00

  • PRM36 NONPARAMETRIC ESTIMATION OF INCREMENTAL COST EFFECTIVENESS RATIO ACCOUNTING FOR SKEWNESS

    May 1, 2011, 00:00

  • CN4 PALONOSETRON VERSUS OTHER 5-HYDROXYTRYPTAMINE3 RECEPTOR ANTAGONISTS FOR PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING AMONG MEDICARE PATIENTS WITH CANCER

    May 1, 2011, 00:00

  • PRM8 LEGAL RESTRICTIONS ON THE USE OF QALYS IN PHARMACOECONOMIC ANALYSIS IN GERMANY

    May 1, 2011, 00:00

  • PIN9 BUDGET IMPACT MODEL OF ABACAVIR/LAMIVUDINE FOR TREATMENT OF HIV INFECTED PATIENTS IN MEXICO

    May 1, 2011, 00:00

  • PIN14 ECONOMIC BURDEN OF SEVERE SEPSIS IN A VERTICALLY INTEGRATED HEALTH CARE SYSTEM (IHS)

    May 1, 2011, 00:00

  • PND28 THE RELATIONSHIP BETWEEN ALTERNATIVE MEDICATION POSESSION RATIO THRESHOLDS AND OUTCOMES- EVIDENCE FROM THE USE OF GLATIRAMER ACETATE

    May 1, 2011, 00:00

  • PSY59 IMPACT OF OBESITY ON AGE-SPECIFIC PREVALENCE OF CHRONIC DISEASES IN THE UNITED STATES

    May 1, 2011, 00:00

  • PCV94 ANTICOAGULANT USE, THE PREVALENCE OF BRIDGING AND RELATION TO LENGTH OF STAY AMONG HOSPITALIZED PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

    May 1, 2011, 00:00

  • PCN127 METHODS FOR INDIRECT COMPARISON OF EFFECTIVENESS IN COST-EFFECTIVENESS ANALYSES OF ONCOLOGY AGENTS- THE PROPORTIONAL HAZARDS ASSUMPTION MATTERS

    May 1, 2011, 00:00

  • PDB27 COST-EFFECTIVENESS ANALYSIS OF METFORMIN COMBINED WITH SAXAGLIPTIN VERSUS METFORMIN COMBINED WITH SULFONYLUREAS IN TYPE-2 DIABETES PATIENTS IN CHILE

    May 1, 2011, 00:00

  • PHP108 THE CASE OF RARE DISEASE DRUGS BEFORE AND AFTER THE INTRODUCTION OF PRICING BODIES- LESSONS LEARNED FROM BRAZIL AND CANADA, IMPLICATIONS FOR THE UNITED STATES

    May 1, 2011, 00:00

  • PRM18 CAN UTILITIES EXCEED 1.0? EMPIRICAL EVIDENCE OF THE CEILING EFFECT

    May 1, 2011, 00:00

  • PRM16 VALIDATION AND PSYCHOMETRIC EVALUATION OF A 5-ITEM MEASURE OF PERCEIVED SOCIAL SUPPORT

    May 1, 2011, 00:00

  • EV4 MORE BANG FOR YOUR BUCK- TAKE A RISK WHEN ANALYSING INTERVIEW DATA

    May 1, 2011, 00:00

  • PIH28 FATIGUE MANAGEMENT- EXAMPLE AT WOMEN WORKING IN PHARMACY

    May 1, 2011, 00:00

  • PCV31 ASSOCIATION BETWEEN HEART FAILURE AND IN-HOSPITAL MORTALITY IN ST-ELEVATION MYOCARDIAL INFARCTION PATIENTS TREATED WITH PERCUTANEOUS CORONARY INTERVENTION

    May 1, 2011, 00:00

  • PDB30 A CROSS-SECTIONAL SURVEY ON ECONOMIC BURDEN OF TYPE-2 DIABETES MELLITUS PATIENTS WITH ORAL ANTI-DIABETIC DRUGS THERAPY IN CHINA

    May 1, 2011, 00:00

  • PND59 MEDICATION TREATMENT PATTERNS FOR MULTIPLE SCLEROSIS PATIENTS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM

    May 1, 2011, 00:00

  • PSY70 ASSOCIATION OF PROVIDER CONTINUITY WITH HOSPITALIZATION AMONG FLORIDA MEDICAID ENROLLEES WITH SICKLE CELL DISEASE (SCD)

    May 1, 2011, 00:00

  • PIH12 INPATIENT COSTS OF LOW BIRTH WEIGHT AND PRE-TERM INFANTS IN THE UNITED STATES IN 2008

    May 1, 2011, 00:00

  • PRM43 BIOSIMILARS- DEMONSTRATING SIMILARITY THROUGH EVIDENCE

    May 1, 2011, 00:00

  • PRM33 TAKE TIME TO TRAIN- EVIDENCE TO SHOW THAT PATIENT TRAINING IN ELECTRONIC PATIENT REPORTED OUTCOMES IS BENEFICIAL

    May 1, 2011, 00:00

  • PND51 THE EFFECT OF THE MEDICARE PART D COVERAGE GAP AND OUT-OF-POCKET BURDEN ON THE USE OF DISEASE MODIFYING DRUGS TO TREAT MULTIPLE SCLEROSIS

    May 1, 2011, 00:00

  • PIN53 COMPARISON OF EVIDENCE-BASED VARIATION AND CONSTANT PERCENTAGE VARIATION FOR ONE-WAY SENSITIVITY ANALYSES

    May 1, 2011, 00:00

  • PSU14 HEALTH-RELATED QUALITY OF LIFE FOR PATIENTS ON KIDNEY TRANSPLANT WAITING LIST - WHAT FACTORS REALLY MATTER?

    May 1, 2011, 00:00

  • Editorial Board

    May 1, 2011, 00:00

  • PIN3 A META-ANALYSIS OF EFFICACY AND SAFETY OF LINEZOLID FOR INFECTED DIABETIC FOOT TREATMENT

    May 1, 2011, 00:00

  • PHP93 AN EXAMINATION OF HOSPITAL-ACQUIRED CONDITIONS BY AGE AND PAYER IN FIFTEEN STATES, 2008

    May 1, 2011, 00:00

  • PIH5 RISK OF HIP AND SUBTROCHANTERIC OR DIAPHYSEAL FEMORAL FRACTURES IN ALENDRONATE USERS

    May 1, 2011, 00:00

  • PSY49 PREDICTORS OF OBESITY TREATMENT (COUNSELING OR PHARMACOTHERAPY) IN AMBULATORY SETTINGS

    May 1, 2011, 00:00

  • PMS63 SATISFACTION, PREFERENCE AND REASONS FOR BIOLOGIC TREATMENT DISCONTINUATION IN PATIENTS WITH RHEUMATOID ARTHRITIS

    May 1, 2011, 00:00

  • PSY56 CONTROLLED SUBSTANCE PRESCRIBING AND UTILIZATION OF PRESCRIPTION DRUG MONITORING PROGRAMS

    May 1, 2011, 00:00

  • PCN64 ECONOMIC EVALUATION OF THREE FORMULATIONS OF LEUPROLIDE ACETATE IN ANDROGEN DEPRIVATION THERAPY FOR ADVANCED PROSTATE CANCER IN BELGIUM

    May 1, 2011, 00:00

  • Table of Contents

    May 1, 2011, 00:00

  • PIN19 COST-BENEFIT ANALYSIS OF POSTPARTUM VACCINATION OF BIRTH MOTHERS WITH INFLUENZA VACCINE

    May 1, 2011, 00:00

  • PDB53 PRESCRIBING PATTERN OF ANTIDIABETIC DRUGS IN T2DM PATIENTS TERTIARY CARE HOSPITAL IN INDIA

    May 1, 2011, 00:00

  • PDB34 PHARMACOECONOMIC EVALUATION OF A PHARMACIST-MANAGED DIABETES CLINIC

    May 1, 2011, 00:00

  • PHP73 SYSTEMATIC LITERATURE REVIEW ON HETEROGENEITY OF RELATIVE EFFECTIVENESS AND RELATIVE EFFICACY OF MEDICINES IN EUROPE

    May 1, 2011, 00:00

  • PHP51 MORTALITY AFTER SPOUSAL BEREAVEMENT IN BENEFICIARIES OF THE HEALTH PLAN

    May 1, 2011, 00:00

  • PCN46 HEALTH CARE EXPENDITURES, DISABILITY DAYS, AND RESOURCE UTILIZATION ASSOCIATED WITH CANCER IN EMPLOYER SETTINGS IN THE UNITED STATES

    May 1, 2011, 00:00

  • PCN13 REAL LIFE OUTCOMES IN 2ND LINE ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)- A PILOT STUDY IN FRANCE AND GERMANY ANALYSING ERLOTINIB VERSUS CHEMOTHERAPY

    May 1, 2011, 00:00

  • PUK17 UTILIZATION AND ECONOMIC IMPACT OF IV IRON AND ERYTHROPOIESIS STIMULATING AGENTS IN CHRONIC KIDNEY DISEASE PATIENTS- A MULTI-HOSPITAL STUDY

    May 1, 2011, 00:00

  • PIN31 COST-EFFECTIVENESS ANALYSIS OF DIFFERENT APPROACHES TO THE DIAGNOSIS AND TREATMENT OF INFLUENZA-LIKE ILLNESS IN HEALTHY ADULTS

    May 1, 2011, 00:00

  • PDB5 THE IMPACT OF ANTIDIABETIC-INDUCED HYPOGLYCEMIA ON CLINICAL OUTCOMES AND RESOURCE UTILIZATION AMONG VETERANS WITH TYPE-2 DIABETES MELLITUS (T2DM)

    May 1, 2011, 00:00

  • PIH22 PRIMARY MEDICATION NONADHERENCE- A RETROSPECTIVE ANALYSIS OF ELECTRONIC PRESCRIPTIONS IN AN INTEGRATED HEALTHCARE SETTING

    May 1, 2011, 00:00

  • PDB4 MODELING HEALTH AND ECONOMIC OUTCOMES ASSOCIATED WITH EXENATIDE ONCE-WEEKLY VERSUS INSULIN AND PIOGLITAZONE TREATMENT FOR TYPE-2 DIABETES

    May 1, 2011, 00:00

  • PCV43 COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN VERSUS DABIGATRAN AND ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP REPLACEMENT

    May 1, 2011, 00:00

  • PND56 COMPARISON OF THE HEALTH CARE UTILIZATION AND COSTS OF MEDICALLY MANAGED PATIENTS VERSUS DEEP BRAIN STUMULATION PATIENTS WITH PARKINSON'S DISEASE

    May 1, 2011, 00:00

  • PRS8 DISEASE PROGRESSION IN CYSTIC FIBROSIS — SYNTHESIS OF SURVIVAL EVIDENCE

    May 1, 2011, 00:00

  • PDB38 A COMPARISON OF INSULIN ADHERENCE IN PATIENTS WITH TYPE-2 DIABETES INITIATING THERAPY WITH INSULIN DETEMIR FLEXPEN® OR NPH INSULIN IN A VIAL

    May 1, 2011, 00:00

  • PSU25 IDENTIFYING IMPROVEMENT OF PRESSURE ULCER PREVENTION AT THE POINT-OF-CARE WITH MULTIPLE METHODS IN THE DEPARTMENT OF SURGERY

    May 1, 2011, 00:00

  • PRS2 INCREASED PREVALENCE OF OBSTRUCTIVE LUNG DISEASE IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA

    May 1, 2011, 00:00

  • PCN118 PREDICTING THE FUTURE IMPACT OF EMERGING TECHNOLOGIES ON HEPATOCELLULAR CARCINOMA (HCC)- MEASURING STAKEHOLDERS PREFERENCES WITH BEST-WORST SCALING

    May 1, 2011, 00:00

  • PCN36 COST ANALYSIS, SAFETY, AND EFFICACY OF PEMETREXED/CISPLATIN COMPARED WITH BEVACIZUMAB/GEMCITABINE/CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED NON-SQUAMOUS NSCLC IN RUSSIA

    May 1, 2011, 00:00

  • PDB2 EVALUATING ONE-YEAR STABILITY OF THE TOTAL ILLNESS BURDEN INDEX

    May 1, 2011, 00:00

  • PRM17 DEVELOPMENT AND VALIDATION OF A HEALTH RELATED QUALITY OF LIFE INSTRUMENT TO MEASURE THE IMPACT OF OVER-THE-COUNTER PRODUCT USE AND ASSOCIATED ADVERSE EVENTS

    May 1, 2011, 00:00

  • PHP4 WHEN STAKEHOLDERS DON'T AGREE- DISCREPANCIES IN MAB “APPROVALS” OVER THE PAST TEN YEARS

    May 1, 2011, 00:00

  • PHP62 WHAT IS THE IMPACT OF COMPARATIVE EFFECTIVENESS AND VALUE BASED PRICING ON A PRODUCT'S VALUE AND MARKET ACCESS?

    May 1, 2011, 00:00

  • OR3 THE DIRECT AND INDIRECT COSTS ASSOCIATED WITH HYPOGONADISM AMONG PRIVATELY-INSURED EMPLOYEES IN THE UNITED STATES

    May 1, 2011, 00:00

  • PCV63 THE IMPACT OF CARDIOVASCULAR DISEASE HOSPITALIZATIONS ON CHANGES IN PATIENT ADHERENCE TO ANTIHYPERTENISVE DRUGS IN A MEDICAID POPULATION

    May 1, 2011, 00:00

  • PRM49 TRANSLATION AND LINGUISTIC VALIDATION – METHODOLOGICAL IMPLICATIONS WHEN THE SOURCE MEASURE IS NOT ENGLISH

    May 1, 2011, 00:00
  • «
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128 (current)
  • 129
  • 130
  • »